New drug LW402 takes first step: safety check in 36 volunteers

NCT ID NCT07546149

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested the safety and tolerability of LW402 tablets in 36 healthy volunteers. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moves through the body. Since this is a Phase 1 study, the main goal is to see if the drug is safe enough to test in larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LW402 tablets

What this could lead to

If successful, this could pave the way for future studies of LW402 as a potential treatment for an unspecified condition.

What could go wrong

This is a very early Phase 1 trial with only 36 healthy volunteers, so it cannot prove the drug works for any disease. Side effects or lack of tolerability may stop further development.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SAFETY EVALUATION OF ESCALATING DOSES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Shandong First Medical University

    Jinan, Shangdong, China